AbbVie Inc. (ABBV)
Pre-market:
| Previous close | 147.40 |
| Open | 147.31 |
| Bid | 145.75 x 1100 |
| Ask | 146.88 x 1400 |
| Day's range | 146.01 - 147.68 |
| 52-week range | 133.05 - 175.91 |
| Volume | |
| Avg. volume | 5,483,988 |
| Market cap | 258.693B |
| Beta (5Y monthly) | 0.62 |
| PE ratio (TTM) | 19.50 |
| EPS (TTM) | 7.50 |
| Earnings date | 09 Feb 2023 |
| Forward dividend & yield | 5.92 (4.05%) |
| Ex-dividend date | 12 Jan 2023 |
| 1y target est | 163.05 |
- Motley Fool
2 of the Best Dividend Stocks to Own in 2023
In either case, it's a good idea to add some dividend stocks to your portfolio. If you want to benefit from passive income and potential growth, I've got two stocks in mind. The stocks I'm talking about also have reached a turning point that could lead to earnings growth down the road.
- Motley Fool
3 Reasons to Buy AbbVie and 2 Reasons Not to Buy
2023 is expected to be an important year for AbbVie (NYSE: ABBV). The pharmaceutical company is facing its first biosimilar competition in the United States. It's big news because it involves AbbVie's monoclonal antibody blockbuster therapy, Humira, which is on track to generate a second consecutive year of $20 billion-plus in revenue in 2022.
- Motley Fool
Want Safety and Growth in 2023? Try These Dividend Stocks.
Last year was a tough one for most companies and investors. The three major indexes touched bear territory. And even the strongest of companies saw their share prices slip. Everyone is hoping 2023 will bring better days.
